Urogen Pharma Ltd (URGN) Stock Price, Quote & News

Company Profile

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution design...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 768 9780

Website: www.urogen.com

Address:

400 Alexander Park Drive, 4th Floor, Princeton, United States

Sowa5000 Oct. 25 at 2:22 AM

$URGN looking forward to earnings..future is good

0 · Reply

deweyeggbert Oct. 25 at 1:23 AM

$URGN Looking at the chart and price action, I believe this is about to go parabolic. Extra bullish!

0 · Reply

deweyeggbert Oct. 24 at 5:39 PM

$URGN You mean Truist, one of the top 10 banks that have nothing to do with Trump? That Truist?

1 · Reply

paulk423 Oct. 24 at 5:27 PM

$URGN Trumps Truist just bought 400k shares apparently. Must have insider info on FDA approval for their cancer drug. It’s going to moon shortly.

1 · Reply

StardustNdreams Oct. 23 at 7:12 PM

$URGN would love to see green on this today still watching it today

0 · Reply

chickenboy Oct. 23 at 5:28 PM

$URGN Anyone have any thoughts on the +10k open interest at $19 call option for December? Seems very bullish.

1 · Reply

DrevanTheStillblade Oct. 22 at 6:11 PM

GIPR is a hidden monster in the small‑cap world. Massively undervalued compared to what it holds—real estate assets over $91 M and trading near ~4.4 M float. No heavy borrow, minimal short interest (~1.4% of float). With a golden cross brewing, this could be the breakout engine many miss. $URGN $BLPH $TDAC $FCEL $BCTX

0 · Reply

Jgdamm Oct. 21 at 2:24 PM

$URGN Is this going to $20-21 pre earnings?

1 · Reply

Masonsy Oct. 18 at 2:36 AM

$URGN does anyone have the same first thought - Trump Financial Corp invests in URGN, while see the news below?

2 · Reply

deweyeggbert Oct. 16 at 10:45 PM

$URGN $SRPT looks like both are setting up for a big move up.

0 · Reply

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 8:00 AM EDT - 2 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

Aug 18, 2025, 3:34 PM EDT - 2 months ago

UroGen Pharma: Targeting Profits In 2027

Aug 9, 2025, 3:05 AM EDT - 2 months ago

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:00 AM EDT - 2 months ago

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 2 months ago

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 29, 2025, 8:00 AM EDT - 3 months ago

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Jul 28, 2025, 8:00 AM EDT - 3 months ago

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

Jul 21, 2025, 8:00 AM EDT - 3 months ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 7, 2025, 8:00 AM EDT - 3 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jun 16, 2025, 8:17 AM EDT - 4 months ago

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

Jun 15, 2025, 10:17 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 13, 2025, 1:05 PM EDT - 4 months ago

UroGen Pharma: Lessons Learned And Future Outlook

Jun 12, 2025, 6:04 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 12, 2025, 1:28 PM EDT - 4 months ago

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 12, 2025, 12:48 PM EDT - 4 months ago

US FDA approves Urogen's bladder cancer drug

Jun 10, 2025, 10:30 AM EDT - 4 months ago

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation

Jun 10, 2025, 8:47 AM EDT - 4 months ago

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

Jun 9, 2025, 1:36 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

Jun 8, 2025, 8:18 AM EDT - 4 months ago

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Jun 5, 2025, 9:31 AM EDT - 5 months ago

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

Jun 4, 2025, 3:46 PM EDT - 5 months ago

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 3, 2025, 3:33 PM EDT - 5 months ago

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Jun 3, 2025, 12:19 PM EDT - 5 months ago

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Jun 3, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

Jun 2, 2025, 11:00 AM EDT - 5 months ago

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Jun 2, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 5 months ago

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 1, 2025, 10:00 AM EDT - 5 months ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Sowa5000 Oct. 25 at 2:22 AM

$URGN looking forward to earnings..future is good

0 · Reply

deweyeggbert Oct. 25 at 1:23 AM

$URGN Looking at the chart and price action, I believe this is about to go parabolic. Extra bullish!

0 · Reply

deweyeggbert Oct. 24 at 5:39 PM

$URGN You mean Truist, one of the top 10 banks that have nothing to do with Trump? That Truist?

1 · Reply

paulk423 Oct. 24 at 5:27 PM

$URGN Trumps Truist just bought 400k shares apparently. Must have insider info on FDA approval for their cancer drug. It’s going to moon shortly.

1 · Reply

StardustNdreams Oct. 23 at 7:12 PM

$URGN would love to see green on this today still watching it today

0 · Reply

chickenboy Oct. 23 at 5:28 PM

$URGN Anyone have any thoughts on the +10k open interest at $19 call option for December? Seems very bullish.

1 · Reply

DrevanTheStillblade Oct. 22 at 6:11 PM

0 · Reply

Jgdamm Oct. 21 at 2:24 PM

$URGN Is this going to $20-21 pre earnings?

1 · Reply

Masonsy Oct. 18 at 2:36 AM

$URGN does anyone have the same first thought - Trump Financial Corp invests in URGN, while see the news below?

2 · Reply

deweyeggbert Oct. 16 at 10:45 PM

$URGN $SRPT looks like both are setting up for a big move up.

0 · Reply

hegdaom Oct. 15 at 2:14 PM

$CAPR $SRPT $URGN $PFE $NVO

0 · Reply

Pukkaa56 Oct. 14 at 12:30 PM

$URGN

1 · Reply

chickenboy Oct. 11 at 2:39 PM

$URGN I don't know which is worse, this stock's price action or me crawling back to it every week thinking I know what is going on. Still

1 · Reply

deweyeggbert Oct. 11 at 1:53 AM

$URGN I suspect there will be a buyout soon. $23 to 27 price. I've been wrong before.

1 · Reply

deweyeggbert Oct. 10 at 10:57 PM

$URGN Unfortunately it broke down out of its $17-$20 accumulation pattern. The positive is that we can buy more for less. It is now trading below the $17 buyout offer that came up a couple of years ago. Now holding 8000 shares and a boatload of calls.

0 · Reply